Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3196165 Long-term Safety in Rheumatoid Arthritis (Extension)
CTR20220414Phase 3Terminated
- Sponsor
- GSK
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of otilimab in rheumatoid arthritis (RA) (2 arms), sponsored by GSK. Primary endpoints: Incidence of adverse events (AE), serious adverse events (SAE) and adverse events of special interest (AESI), Change from baseline in key laboratory parameters and 1 more. Started Mar 2022; status: terminated.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20220414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220414.